[{"orgOrder":0,"company":"Ipsen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Palovarotene","moa":"RAR-gamma","graph1":"Genetic Disease","graph2":"Approved","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"Ipsen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ipsen \/ Not Applicable"},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"10153627","moa":"IBAT","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Albireo Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Albireo Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Albireo Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Ipsen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Fluorouracil","moa":"DNA","graph1":"Oncology","graph2":"Phase III","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ipsen \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ipsen \/ Not Applicable"},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Elobixibat","moa":"IBAT","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Albireo Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Albireo Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Albireo Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Ipsen","sponsor":"The University of Texas MD Anderson Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UKRAINE","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"IPN60090","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ipsen \/ The University of Texas MD Anderson Cancer Center","highestDevelopmentStatusID":"6","companyTruncated":"Ipsen \/ The University of Texas MD Anderson Cancer Center"},{"orgOrder":0,"company":"Ipsen","sponsor":"University of Montreal","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Undisclosed","year":"2020","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Ipsen \/ University of Montreal","highestDevelopmentStatusID":"2","companyTruncated":"Ipsen \/ University of Montreal"},{"orgOrder":0,"company":"Ipsen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"FRANCE","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Botulinum toxin type A","moa":"SNAP-25","graph1":"Musculoskeletal","graph2":"Phase IV","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ipsen \/ Not Applicable","highestDevelopmentStatusID":"11","companyTruncated":"Ipsen \/ Not Applicable"},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Hercules Capital","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Financing","leadProduct":"Elobixibat","moa":"IBAT","graph1":"Gastroenterology","graph2":"Approved","graph3":"Albireo Pharma","amount2":0.11,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","amount2New":0.11,"dosageForm":"","sponsorNew":"Albireo Pharma \/ Hercules Capital","highestDevelopmentStatusID":"12","companyTruncated":"Albireo Pharma \/ Hercules Capital"},{"orgOrder":0,"company":"Ipsen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Palovarotene","moa":"RAR-gamma","graph1":"Genetic Disease","graph2":"Approved","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"Ipsen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ipsen \/ Not Applicable"},{"orgOrder":0,"company":"Ipsen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Irinotecan Hydrochloride","moa":"DNA Topoisomerase I","graph1":"Oncology","graph2":"Phase III","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Ipsen \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ipsen \/ Not Applicable"},{"orgOrder":0,"company":"Ipsen","sponsor":"Exelixis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Small molecule","year":"2020","type":"Collaboration","leadProduct":"Cabozantinib","moa":"VEGFR2","graph1":"Oncology","graph2":"Phase III","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Ipsen \/ Exelixis","highestDevelopmentStatusID":"10","companyTruncated":"Ipsen \/ Exelixis"},{"orgOrder":0,"company":"Ipsen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Irinotecan Hydrochloride","moa":"DNA Topoisomerase I","graph1":"Oncology","graph2":"Phase III","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Ipsen \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ipsen \/ Not Applicable"},{"orgOrder":0,"company":"Ipsen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"FRANCE","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Botulinum toxin type A","moa":"SNAP-25","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Ipsen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ipsen \/ Not Applicable"},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Odevixibat","moa":"IBAT","graph1":"Genetic Disease","graph2":"Approved","graph3":"Albireo Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Albireo Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Albireo Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Elobixibat","moa":"IBAT","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Albireo Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Albireo Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Albireo Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Ipsen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Palovarotene","moa":"RAR-gamma","graph1":"Genetic Disease","graph2":"Approved","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"Ipsen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ipsen \/ Not Applicable"},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Odevixibat","moa":"IBAT","graph1":"Genetic Disease","graph2":"Approved","graph3":"Albireo Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Albireo Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Albireo Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Odevixibat","moa":"IBAT","graph1":"Genetic Disease","graph2":"Approved","graph3":"Albireo Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Albireo Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Albireo Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Ipsen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Cabozantinib","moa":"VEGFR2","graph1":"Oncology","graph2":"Approved","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ipsen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ipsen \/ Not Applicable"},{"orgOrder":0,"company":"Ipsen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Palovarotene","moa":"RAR-gamma","graph1":"Genetic Disease","graph2":"Approved","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ipsen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ipsen \/ Not Applicable"},{"orgOrder":0,"company":"Ipsen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Peptide","year":"2020","type":"Not Applicable","leadProduct":"Lanreotide Acetate","moa":"SSTR2","graph1":"Oncology","graph2":"Phase II","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ipsen \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ipsen \/ Not Applicable"},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Odevixibat","moa":"IBAT","graph1":"Genetic Disease","graph2":"Approved","graph3":"Albireo Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Albireo Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Albireo Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Odevixibat","moa":"IBAT","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Albireo Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"capsule","sponsorNew":"Albireo Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Albireo Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Odevixibat","moa":"IBAT","graph1":"Genetic Disease","graph2":"Approved","graph3":"Albireo Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"capsule","sponsorNew":"Albireo Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Albireo Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Odevixibat","moa":"IBAT","graph1":"Genetic Disease","graph2":"Approved","graph3":"Albireo Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"capsule","sponsorNew":"Albireo Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Albireo Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Odevixibat","moa":"IBAT","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Albireo Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Albireo Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Albireo Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Ipsen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Botulinum toxin type A","moa":"SNAP25","graph1":"Neurology","graph2":"Phase IV","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Ipsen \/ Not Applicable","highestDevelopmentStatusID":"11","companyTruncated":"Ipsen \/ Not Applicable"},{"orgOrder":0,"company":"Ipsen","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Cabozantinib","moa":"VEGFR2","graph1":"Oncology","graph2":"Approved","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ipsen \/ Bristol Myers Squibb","highestDevelopmentStatusID":"12","companyTruncated":"Ipsen \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Ipsen","sponsor":"Fusion Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Small molecule","year":"2021","type":"Acquisition","leadProduct":"Actinium-225","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Ipsen","amount2":0.57999999999999996,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.57999999999999996,"dosageForm":"","sponsorNew":"Ipsen \/ Fusion Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Ipsen \/ Fusion Pharmaceuticals"},{"orgOrder":0,"company":"Ipsen","sponsor":"Exelixis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Collaboration","leadProduct":"Cabozantinib","moa":"MET","graph1":"Oncology","graph2":"Approved","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ipsen \/ Ipsen","highestDevelopmentStatusID":"12","companyTruncated":"Ipsen \/ Ipsen"},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Odevixibat","moa":"IBAT","graph1":"Genetic Disease","graph2":"Approved","graph3":"Albireo Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Albireo Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Albireo Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Ipsen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Palovarotene","moa":"RAR gamma","graph1":"Genetic Disease","graph2":"Approved","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ipsen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ipsen \/ Not Applicable"},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Odevixibat","moa":"IBAT","graph1":"Genetic Disease","graph2":"Approved","graph3":"Albireo Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Albireo Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Albireo Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Odevixibat","moa":"IBAT","graph1":"Genetic Disease","graph2":"Approved","graph3":"Albireo Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Albireo Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Albireo Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Odevixibat","moa":"IBAT","graph1":"Genetic Disease","graph2":"Approved","graph3":"Albireo Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Albireo Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Albireo Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Ipsen","sponsor":"Exelixis","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Cabozantinib","moa":"MET","graph1":"Oncology","graph2":"Approved","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ipsen \/ Exelixis","highestDevelopmentStatusID":"12","companyTruncated":"Ipsen \/ Exelixis"},{"orgOrder":0,"company":"Ipsen","sponsor":"Exelixis","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ipsen \/ Ipsen","highestDevelopmentStatusID":"10","companyTruncated":"Ipsen \/ Ipsen"},{"orgOrder":0,"company":"Ipsen","sponsor":"BAKX Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Collaboration","leadProduct":"BKX-001","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Ipsen","amount2":0.84999999999999998,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.84999999999999998,"dosageForm":"Oral","sponsorNew":"Ipsen \/ Ipsen","highestDevelopmentStatusID":"4","companyTruncated":"Ipsen \/ Ipsen"},{"orgOrder":0,"company":"Ipsen","sponsor":"Exicure","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"IRELAND","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"SNA-based Therapeutics","moa":"","graph1":"Genetic Disease","graph2":"Discovery","graph3":"Ipsen","amount2":1.02,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","amount2New":1.02,"dosageForm":"","sponsorNew":"Ipsen \/ Ipsen","highestDevelopmentStatusID":"2","companyTruncated":"Ipsen \/ Ipsen"},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Genpharma","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Partnership","leadProduct":"Odevixibat","moa":"IBAT","graph1":"Genetic Disease","graph2":"Approved","graph3":"Albireo Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Albireo Pharma \/ Genpharm","highestDevelopmentStatusID":"12","companyTruncated":"Albireo Pharma \/ Genpharm"},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Jefferies LLC","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Divestment","leadProduct":"Odevixibat","moa":"IBAT","graph1":"Genetic Disease","graph2":"Approved","graph3":"Albireo Pharma","amount2":0.11,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0.11,"dosageForm":"Capsule","sponsorNew":"Albireo Pharma \/ Jefferies LLC","highestDevelopmentStatusID":"12","companyTruncated":"Albireo Pharma \/ Jefferies LLC"},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Jadeite Medicines","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Odevixibat","moa":"IBAT","graph1":"Genetic Disease","graph2":"Approved","graph3":"Albireo Pharma","amount2":0.14000000000000001,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0.14000000000000001,"dosageForm":"Capsule","sponsorNew":"Albireo Pharma \/ Jadeite Medicines","highestDevelopmentStatusID":"12","companyTruncated":"Albireo Pharma \/ Jadeite Medicines"},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Odevixibat","moa":"IBAT","graph1":"Genetic Disease","graph2":"Approved","graph3":"Albireo Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Albireo Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Albireo Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Ipsen","sponsor":"Accent Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"METTL3","graph1":"Oncology","graph2":"Preclinical","graph3":"Ipsen","amount2":0.45000000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.45000000000000001,"dosageForm":"","sponsorNew":"Ipsen \/ Ipsen","highestDevelopmentStatusID":"4","companyTruncated":"Ipsen \/ Ipsen"},{"orgOrder":0,"company":"Ipsen","sponsor":"Ipsen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Small molecule","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Dosage Strength\/Form","sponsorNew":"Ipsen \/ Ipsen","highestDevelopmentStatusID":"4","companyTruncated":"Ipsen \/ Ipsen"},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Odevixibat","moa":"IBAT","graph1":"Genetic Disease","graph2":"Approved","graph3":"Albireo Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Albireo Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Albireo Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Ipsen","sponsor":"Genfit","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"FRANCE","productType":"Small molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Elafibranor","moa":"PPAR gamma","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Ipsen","amount2":0.57999999999999996,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0.57999999999999996,"dosageForm":"Tablet","sponsorNew":"Ipsen \/ Ipsen","highestDevelopmentStatusID":"10","companyTruncated":"Ipsen \/ Ipsen"},{"orgOrder":0,"company":"Ipsen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Palovarotene","moa":"RAR-gamma","graph1":"Genetic Disease","graph2":"Approved","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ipsen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ipsen \/ Not Applicable"},{"orgOrder":0,"company":"Ipsen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Cabozantinib","moa":"VEGFR2","graph1":"Oncology","graph2":"Approved","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ipsen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ipsen \/ Not Applicable"},{"orgOrder":0,"company":"Ipsen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"Lanreotide Acetate","moa":"SSTR2","graph1":"Oncology","graph2":"Approved","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ipsen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ipsen \/ Not Applicable"},{"orgOrder":0,"company":"Ipsen","sponsor":"Phillips - Medisize","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Peptide","year":"2022","type":"Financing","leadProduct":"Lanreotide Acetate","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Ipsen \/ Phillips-Medisize","highestDevelopmentStatusID":"12","companyTruncated":"Ipsen \/ Phillips-Medisize"},{"orgOrder":0,"company":"Ipsen","sponsor":"Galderma","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Botulinum toxin type A","moa":"Ach release","graph1":"Dermatology","graph2":"Approved","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Ipsen \/ Ipsen","highestDevelopmentStatusID":"12","companyTruncated":"Ipsen \/ Ipsen"},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Odevixibat","moa":"IBAT","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Albireo Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Albireo Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Albireo Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Ipsen","sponsor":"Exelixis","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Cabozantinib","moa":"MET","graph1":"Oncology","graph2":"Approved","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ipsen \/ Exelixis","highestDevelopmentStatusID":"12","companyTruncated":"Ipsen \/ Exelixis"},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Odevixibat","moa":"IBAT","graph1":"Genetic Disease","graph2":"Approved","graph3":"Albireo Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Albireo Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Albireo Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Ipsen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Cabozantinib","moa":"VEGFR 1\/2\/3","graph1":"Oncology","graph2":"Approved","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ipsen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ipsen \/ Not Applicable"},{"orgOrder":0,"company":"Ipsen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"FRANCE","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Botulinum toxin type A","moa":"SNAP25","graph1":"Urology","graph2":"Phase III","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Ipsen \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ipsen \/ Not Applicable"},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Odevixibat","moa":"IBAT","graph1":"Genetic Disease","graph2":"Approved","graph3":"Albireo Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Albireo Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Albireo Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Odevixibat","moa":"IBAT","graph1":"Genetic Disease","graph2":"Approved","graph3":"Albireo Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Albireo Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Albireo Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Ipsen","sponsor":"Epizyme","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Acquisition","leadProduct":"Tazemetostat","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ipsen \/ Ipsen","highestDevelopmentStatusID":"12","companyTruncated":"Ipsen \/ Ipsen"},{"orgOrder":0,"company":"Ipsen","sponsor":"Fusion Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"225Ac-IPN-1087","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Ipsen \/ Ipsen","highestDevelopmentStatusID":"5","companyTruncated":"Ipsen \/ Ipsen"},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Odevixibat","moa":"IBAT","graph1":"Genetic Disease","graph2":"Approved","graph3":"Albireo Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Albireo Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Albireo Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Ipsen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Palovarotene","moa":"RAR-gamma","graph1":"Genetic Disease","graph2":"Approved","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ipsen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ipsen \/ Not Applicable"},{"orgOrder":0,"company":"Ipsen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Irinotecan Hydrochloride","moa":"DNA Topoisomerase I","graph1":"Oncology","graph2":"Phase III","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Ipsen \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ipsen \/ Not Applicable"},{"orgOrder":0,"company":"Ipsen","sponsor":"Merrimack Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Irinotecan Hydrochloride","moa":"DNA Topoisomerase I","graph1":"Oncology","graph2":"Phase III","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Ipsen \/ Merrimack Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Ipsen \/ Merrimack Pharmaceuticals"},{"orgOrder":0,"company":"Ipsen","sponsor":"Epizyme","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Acquisition","leadProduct":"Tazemetostat","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ipsen \/ Ipsen","highestDevelopmentStatusID":"12","companyTruncated":"Ipsen \/ Ipsen"},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Medison Pharma","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"ISRAEL","productType":"Small molecule","year":"2022","type":"Partnership","leadProduct":"Odevixibat","moa":"IBAT","graph1":"Genetic Disease","graph2":"Approved","graph3":"Albireo Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Albireo Pharma \/ Albireo","highestDevelopmentStatusID":"12","companyTruncated":"Albireo Pharma \/ Albireo"},{"orgOrder":0,"company":"Ipsen","sponsor":"IRLAB","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Mesdopetam","moa":"D3 receptor","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ipsen \/ IRLAB","highestDevelopmentStatusID":"9","companyTruncated":"Ipsen \/ IRLAB"},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Odevixibat","moa":"IBAT","graph1":"Genetic Disease","graph2":"Approved","graph3":"Albireo Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Albireo Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Albireo Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Sagard","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Agreement","leadProduct":"Odevixibat","moa":"IBAT","graph1":"Dermatology","graph2":"Approved","graph3":"Albireo Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Albireo Pharma \/ Sagard","highestDevelopmentStatusID":"12","companyTruncated":"Albireo Pharma \/ Sagard"},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Odevixibat","moa":"IBAT","graph1":"Genetic Disease","graph2":"Approved","graph3":"Albireo Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Albireo Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Albireo Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Odevixibat","moa":"IBAT","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Albireo Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Albireo Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Albireo Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Odevixibat","moa":"IBAT","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Albireo Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Albireo Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Albireo Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Odevixibat","moa":"IBAT","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Albireo Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Albireo Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Albireo Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Odevixibat","moa":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Albireo Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Albireo Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Albireo Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Ipsen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Cabozantinib","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ipsen \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ipsen \/ Not Applicable"},{"orgOrder":0,"company":"Ipsen","sponsor":"Exicure","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"IRELAND","productType":"Large molecule","year":"2022","type":"Termination","leadProduct":"SNA-based Therapeutic","moa":"","graph1":"Genetic Disease","graph2":"Discovery","graph3":"Ipsen","amount2":1.02,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","amount2New":1.02,"dosageForm":"","sponsorNew":"Ipsen \/ Ipsen","highestDevelopmentStatusID":"2","companyTruncated":"Ipsen \/ Ipsen"},{"orgOrder":0,"company":"Ipsen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Palovarotene","moa":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ipsen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ipsen \/ Not Applicable"},{"orgOrder":0,"company":"Ipsen","sponsor":"Albireo Pharma","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Acquisition","leadProduct":"Odevixibat","moa":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Ipsen","amount2":0.94999999999999996,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0.94999999999999996,"dosageForm":"Capsule","sponsorNew":"Ipsen \/ Ipsen","highestDevelopmentStatusID":"12","companyTruncated":"Ipsen \/ Ipsen"},{"orgOrder":0,"company":"Ipsen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Irinotecan Hydrochloride","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Ipsen \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ipsen \/ Not Applicable"},{"orgOrder":0,"company":"Ipsen","sponsor":"Marengo Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Partnership","leadProduct":"STAR002","moa":"TCR-V beta","graph1":"Oncology","graph2":"Preclinical","graph3":"Ipsen","amount2":1.5900000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":1.5900000000000001,"dosageForm":"","sponsorNew":"Ipsen \/ Ipsen","highestDevelopmentStatusID":"4","companyTruncated":"Ipsen \/ Ipsen"},{"orgOrder":0,"company":"Ipsen","sponsor":"Ipsen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Undisclosed","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Ipsen \/ Ipsen","highestDevelopmentStatusID":"2","companyTruncated":"Ipsen \/ Ipsen"},{"orgOrder":0,"company":"Ipsen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Cabozantinib","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ipsen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ipsen \/ Not Applicable"},{"orgOrder":0,"company":"Ipsen","sponsor":"Albireo Pharma","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Acquisition","leadProduct":"Odevixibat","moa":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Ipsen","amount2":0.94999999999999996,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0.94999999999999996,"dosageForm":"Capsule","sponsorNew":"Ipsen \/ Ipsen","highestDevelopmentStatusID":"12","companyTruncated":"Ipsen \/ Ipsen"},{"orgOrder":0,"company":"Ipsen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Palovarotene","moa":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ipsen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ipsen \/ Not Applicable"},{"orgOrder":0,"company":"Ipsen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Palovarotene","moa":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ipsen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ipsen \/ Not Applicable"},{"orgOrder":0,"company":"Ipsen","sponsor":"Exelixis","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Cabozantinib","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Ipsen \/ Ipsen","highestDevelopmentStatusID":"12","companyTruncated":"Ipsen \/ Ipsen"},{"orgOrder":0,"company":"Ipsen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Odevixibat","moa":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ipsen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ipsen \/ Not Applicable"},{"orgOrder":0,"company":"Ipsen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Irinotecan Hydrochloride","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Ipsen \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ipsen \/ Not Applicable"},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Jadeite Medicines","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Odevixibat","moa":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Albireo Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Albireo Pharma \/ Albireo Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Albireo Pharma \/ Albireo Pharma"},{"orgOrder":0,"company":"Ipsen","sponsor":"Genfit","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"FRANCE","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Elafibranor","moa":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Ipsen \/ Genfit","highestDevelopmentStatusID":"10","companyTruncated":"Ipsen \/ Genfit"},{"orgOrder":0,"company":"Ipsen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Palovarotene","moa":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ipsen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ipsen \/ Not Applicable"},{"orgOrder":0,"company":"Ipsen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Odevixibat","moa":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"Ipsen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ipsen \/ Not Applicable"},{"orgOrder":0,"company":"Ipsen","sponsor":"Galderma","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"FRANCE","productType":"Large molecule","year":"2023","type":"Termination","leadProduct":"Botulinum toxin type A","moa":"","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Ipsen","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0.040000000000000001,"dosageForm":"Injectable\/Injection","sponsorNew":"Ipsen \/ Galderma","highestDevelopmentStatusID":"7","companyTruncated":"Ipsen \/ Galderma"},{"orgOrder":0,"company":"Ipsen","sponsor":"IRLAB","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"FRANCE","productType":"Small molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Mesdopetam","moa":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ipsen \/ IRLAB","highestDevelopmentStatusID":"9","companyTruncated":"Ipsen \/ IRLAB"},{"orgOrder":0,"company":"Ipsen","sponsor":"Exelixis","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Cabozantinib","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Ipsen \/ Ipsen","highestDevelopmentStatusID":"10","companyTruncated":"Ipsen \/ Ipsen"},{"orgOrder":0,"company":"Ipsen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"FRANCE","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Botulinum toxin type A","moa":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ipsen \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ipsen \/ Not Applicable"},{"orgOrder":0,"company":"Ipsen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Odevixibat","moa":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ipsen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ipsen \/ Not Applicable"},{"orgOrder":0,"company":"Ipsen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Odevixibat","moa":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ipsen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ipsen \/ Not Applicable"},{"orgOrder":0,"company":"Ipsen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Irinotecan Hydrochloride","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Ipsen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ipsen \/ Not Applicable"},{"orgOrder":0,"company":"Ipsen","sponsor":"Merrimack Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Acquisition","leadProduct":"Irinotecan Hydrochloride","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Ipsen","amount2":1.03,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":1.03,"dosageForm":"Infusion","sponsorNew":"Ipsen \/ Ipsen","highestDevelopmentStatusID":"12","companyTruncated":"Ipsen \/ Ipsen"},{"orgOrder":0,"company":"Ipsen","sponsor":"Sutro Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Licensing Agreement","leadProduct":"STRO-003","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Ipsen \/ Ipsen","highestDevelopmentStatusID":"4","companyTruncated":"Ipsen \/ Ipsen"},{"orgOrder":0,"company":"Ipsen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"FRANCE","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Elafibranor","moa":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Ipsen \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ipsen \/ Not Applicable"},{"orgOrder":0,"company":"Ipsen","sponsor":"Skyhawk Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Rare Diseases and Disorders","graph2":"Discovery","graph3":"Ipsen","amount2":1.8,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Rare Diseases","amount2New":1.8,"dosageForm":"","sponsorNew":"Ipsen \/ Ipsen","highestDevelopmentStatusID":"2","companyTruncated":"Ipsen \/ Ipsen"},{"orgOrder":0,"company":"Ipsen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"FRANCE","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Elafibranor","moa":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"","sponsorNew":"Ipsen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ipsen \/ Not Applicable"},{"orgOrder":0,"company":"Ipsen","sponsor":"Marengo Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Partnership","leadProduct":"T Cell Engager","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Ipsen","amount2":1.2,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":1.2,"dosageForm":"","sponsorNew":"Ipsen \/ Ipsen","highestDevelopmentStatusID":"2","companyTruncated":"Ipsen \/ Ipsen"},{"orgOrder":0,"company":"Ipsen","sponsor":"Exelixis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Small molecule","year":"2024","type":"Collaboration","leadProduct":"Cabozantinib","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Ipsen \/ Exelixis","highestDevelopmentStatusID":"10","companyTruncated":"Ipsen \/ Exelixis"},{"orgOrder":0,"company":"Ipsen","sponsor":"Ipsen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Large molecule","year":"2024","type":"Licensing Agreement","leadProduct":"FS001","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Ipsen","amount2":1.03,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Ipsen \/ Ipsen","highestDevelopmentStatusID":"12","companyTruncated":"Ipsen \/ Ipsen"},{"orgOrder":0,"company":"Ipsen","sponsor":"Day One Biopharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Tovorafenib","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Ipsen","amount2":0.46000000000000002,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Ipsen \/ Ipsen","highestDevelopmentStatusID":"12","companyTruncated":"Ipsen \/ Ipsen"},{"orgOrder":0,"company":"Ipsen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"FRANCE","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Elafibranor","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Ipsen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ipsen \/ Not Applicable"},{"orgOrder":0,"company":"Ipsen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Cabozantinib","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Ipsen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ipsen \/ Not Applicable"},{"orgOrder":0,"company":"Ipsen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Cabozantinib","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Ipsen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ipsen \/ Not Applicable"},{"orgOrder":0,"company":"Ipsen","sponsor":"Eton Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Large molecule","year":"2024","type":"Acquisition","leadProduct":"Mecasermin","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Ipsen \/ Eton Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Ipsen \/ Eton Pharmaceuticals"},{"orgOrder":0,"company":"Ipsen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"FRANCE","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Odevixibat","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Ipsen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ipsen \/ Not Applicable"},{"orgOrder":0,"company":"Ipsen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"FRANCE","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Elafibranor","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Ipsen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ipsen \/ Not Applicable"},{"orgOrder":0,"company":"Ipsen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"FRANCE","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Elafibranor","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Ipsen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ipsen \/ Not Applicable"}]
Find Clinical Drug Pipeline Developments & Deals by Ipsen
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
